A Novel Terpenoid from Elephantopus Scaber – Antibacterial Activity on Staphylococcus Aureus: A Substantiate Computational Approach

P. Daisy, Salu Mathew, S. Suveena, Nirmala A. Rayan

Bioinformatics Centre (BIF), Department of Biotechnology & Bioinformatics, Holy Cross College, Tepakulam, Tiruchirapalli-620002, India

ABSTRACT

Staphylococcus aureus has gained much attention in the last decade as it is a major cause of the Urinary Tract Infection in Diabetic patients. The Extended Spectrum β-Lactamases (ESβL) producers are highly resistant to several conventional antibiotics. This limits the therapeutic options. Hence efforts are now taken to screen few medicinal plants, which are both economic and less toxic. Among the several plants screened, we have chosen the acetone extract of Elephantopus scaber from which we purified a new terpenoid for our study. Its structure was generated using CHEMSKETCH software and the activity prediction was done using PASS PREDICTION software. We have confirmed the mechanism of anti-bacterial effect of terpenoid using Computer –Aided Drug Design (CADD) with computational methods to simulate drug – receptor interactions. The Protein-Ligand interaction plays a significant role in the structural based drug designing. In this present study we have taken the Autolysin, the bacteriolytic enzyme, that digest the cell wall peptidoglycan. The autolysin and terpenoid were docked using HEX docking software and the docking score with minimum energy value of -209.54 was calculated. It infer that the terpenoid can inhibit the activity of autolysin by forming a strong atomic interaction with the active site residues. Hence the terpenoid can act as a drug for bacterial infections. Further investigations can be carried out to predict the activity of terpenoid on other targets. (Int J Biomed Sci 2008; 4 (3): 196-203)

Keywords: antibacterial; autolysin; terpenoid; CADD; chemsketch; hex; pass prediction

INTRODUCTION

Diabetes Mellitus (DM) is the most prevalent chronic disease in the world affecting nearly 25% of the popula-
the development of microbial resistance to the available antibiotics has led authors to investigate the antimicrobial activity of medicinal plants (6, 17, 22).

Drug resistance is one of the most serious global threats to the treatment of infectious diseases (21, 27). Therefore, actions must be taken to reduce this problem, for example, to control the use of antibiotic, and develop research to better understand the basic mechanisms of resistance and to continue studies to develop new drugs, either synthetic or natural. Among the several drug resistant bacteria, \(\beta\)-lactamase production is the most important mechanism of resistance to penicillin and cephalosporins. The mechanism of this resistance was the production of Extended Spectrum \(\beta\)-Lactamases (ESBLs) (3). Treatment of infections caused by these resistant bacteria has become very difficult, since they are resistant to many antibiotics. This limits therapeutic options (33). Therefore, alternative methods of treatment are sought after.

There is a continuous and urgent need to discover new antimicrobial compounds with diverse chemical structures and novel mechanisms of action for new and re-emerging infectious diseases. Therefore, researchers are increasingly turning their attention to folk medicine, looking for new leads to develop better drugs against microbial infections (11). Among the several plants screened, *Elephantopus scaber* (*E*. *scaber*), a member of the family Asteraceae known for its medicinal properties was also reported to possess antimicrobial activity (1). Yet, there were no reports on the role of neither the plant nor its compound against the drug-resistant human pathogens. Hence this plant was chosen. A new terpenoid was isolated from the acetone extract of *E*. *scaber*. Biological testing of the compound demonstrated a significant anti-bacterial activity against a few multi drug-resistant ESBL producing clinical isolates (20). But the mechanism of the anti-bacterial effect of the compound was not clearly understood to overcome this we tried in nonconventional methods of drug designing by the use of Bioinformatics approaches.

Bioinformatics is seen as an emerging field with the potential to significantly improve how drugs are found, brought to the clinical trials and eventually released to the marketplace. Bioinformatics can be thought of as a central hub that unites several disciplines and methodologies. Computer-Aided Drug Design (CADD) is a specialized discipline that uses computational methods to simulate drug – receptor interactions. CADD methods are heavily dependent on bioinformatics tools, applications and databases. As such, there is considerable overlap in CADD research and Bioinformatics.

Methods developed to facilitate and speedup the drug designing process are Rational Drug Design (RDD). These processes are used in biopharmaceutical industry to discover and develop new drugs. RDD uses a variety of computational methods to identify novel compounds. One of those methods is docking of drug molecules with receptors. The site of drug action, which is ultimately responsible for the pharmaceutical effect, is a receptor.

Docking allows the scientist to virtually screen a database of compounds and predict the strongest binders based on various scoring functions. It explores ways in which two molecules, such as drugs and an enzyme receptor fit together and dock to each other well. The molecules binding to a receptor, inhibit its function, and thus act as drug. Complexes was identified via docking and their relative stabilities were evaluated using molecular dynamics and their binding affinities, using free energy simulations

Autolysins are bacteriolytic enzymes that digest cell wall peptidoglycan of the bacteria that produce them (32) although potentially lethal; autolysins appear to be universal among bacteria that possess peptidoglycan. Peptidoglycan the substrate of autolysins is a polymer of amyl sugars cross linked by short peptides which forms a covalent matrix that surrounds the cytoplasmic membrane and constitutes the major skeletal component of the cell wall. It is a member of the Metalloprotease Gly-Gly endopeptidase family with PFAM ID PF01551.

The possibility that autolysins are involved in selective removal of peptidoglycan has led to proposals that they are involved in numerous cellular processes including cell growth, cell-wall turnover, peptidoglycan maturation, cell division, separation, motility, chemotaxis, genetic competence, protein secretion, differentiation and pathogenicity (5, 14). Lysis is caused by the presence in the microorganisms of autolytic enzymes (autolysins) which specifically hydrolyse mucoprotein polymers in the bacterial cell wall. The attack occurs, at least in some species, in a very restricted area around the point at which the bacteria will divide (19).

Keeping rational drug designing in mind we made an effort to design natural drug for UT infection caused by *S*. *aureus*, using a novel terpenoid compound isolated from *E*. *scaber* by docking against autolysin.

**MATERIALS AND METHODS**

The dried and powdered *E*. *scaber* plant was used to prepare acetone extract which was then subjected to fractionation on silica gel. The most bioactive fraction ob-
tained from acetone extract of *E. scaber* was selected for preliminary phytochemical screening. Test for alkaloids, steroids, flavanoids, Terpenoids and proteins were carried out according to the standard methods (18). A new Terpenoid was purified for the study.

The bacterial isolates were screened for ESBL production following a double disc synergy test (25). The antibacterial activity of the Terpenoid was evaluated by the disc diffusion method (4). The Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) were determined for the Terpenoid by broth dilution method (2).

For docking study bioinformatics softwares like Pass Prediction, ChemSketch and Hex docking were used. Based on the literature, the present study was confined to the Terpene family of drugs showing antibacterial activity on membrane protein autolysins. The crystal structure of *S. aureus* LytM (13) with resolution 1.50 A. PDB ID 2B0P retrieved from PDB contain chain A and chain B, with PFAM ID PF01551 Peptidase family. Structure contains a long and narrow groove that consists the active site (Fig. 1).

ACD/ChemSketch software is an integrated software package from Advanced Chemistry Development Inc. for drawing chemical structures, 3D optimization algorithm allows the planar (2D) structure from ChemSketch to be rapidly translated into a realistic 3-dimensional structure. It is based on the modified molecular mechanics which take into account, bond stretching, angle bending, internal rotation and Van der Waals non-bonded interactions. The 3D optimization algorithm is a proprietary version of molecular mechanics with the force field initially based on CHARMM parameterization (7, 8). CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. By the help of chemsketch software we have generated the 3D structure of the molecule. The docking analysis of terpenoid with target protein was carried by HEX docking software.

To study the interaction here we have used Swiss pdb viewer. Deep View - Swiss-PdbViewer is an application that provides a user friendly interface allowing analyzing several proteins at the same time. H-bonds, angles and distances between atoms are easy to obtain.

**RESULTS**

The NMR study result of the Terpenoid is given in Fig 2. Based on the NMR study result of Terpenoid the 3D structure was predicted using the ChemSketch Software and the result is given in Fig. 3 and Table 1 explains

![Figure 1. 3D structure of the autolysin PDB id 2B0P.](image1)

![Figure 2. NMR study result of Terpenoid.](image2)

![Figure 3. 3D structure of the compound Terpenoid (809/CHEM/2007) extracted from *E. Scaber*.](image3)
the predicted properties of Terpenoid. Fig. 4 is the structural prediction result of Terpenoid using Pass Prediction to Software. This result shows that the compound will act as an inhibitor for the metalloprotease Gly-Gly-Endopeptidase enzyme family. Fig. 5 shows the structure of the active site loop of the target protein which has consecutive Glycine units at the positions 240, 241, 242. Table 2 showing the docking result. The minimum energy (Emin) value for the protein-ligand complex was calculated. The calculated docking results are given. Fig. 6 depicts the structure binding site of the autolysin protein and the structure of the protein-ligand complex. Fig. 7 & 8 illustrates the computed results of atomic interactions (H-bonds) between the protein and the ligand. Table 3 explains the atoms involved in protein-ligand interaction, calculated Bond length and the positions of amino acid of the active site.

**DISCUSSION**

The active site loop of the target protein containing the 3 consecutive glycine residues does not possess any other functional group other than the amino and the carbonyl group of the peptide bond and they are not involved in the formation of the secondary structures hence these groups are free to have strong atomic interactions with the Terpenoid under study and can easily bind with the loop.
Fig. 6 and table 3 confirms the presence of free amino and carbonyl group of the protein which is tightly bound with the Terpenoid at the positions 20, 21, 22 and 26 respectively.

Since the protein-ligand complex showed $E_{\text{min}} = -209.54$, the novel drug Terpenoid is more compatible with the receptor active site. As the terpenoid can act as a Metalloprotease inhibitor, the activity of the target Autolysin, which also a member of the Metalloprotease-glycine glycine endopeptidase, is inhibited.

Three sorts of hypotheses have been suggested about the mechanism of action of autolysin. First, that the enzymes are essential to make openings in the supposedly continuous network of mucopeptides in the wall (31) so that the new building blocks can be added during growth (29); second, that the enzymes are essential for the remodelling of the wall in making the septum that divides one bacterium into two daughter cells (26, 29); and third, that they are necessary to break the two newly formed bacteria apart from each other (23).

From the literature, the essential oil of *Melaleuca alternifolia* (tea tree) has broad-spectrum antimicrobial ac-

| Table 1. Predicted Properties of Terpenoid |
|------------------------------------------|
| **Calculated properties**               | **Terpenoid**              |
| Molecular Formula                        | C<sub>27</sub>H<sub>38</sub>O<sub>2</sub> |
| Formula Weight                          | 394.58942                  |
| Composition                              | C (82.18%), H (9.71%), O (8.11%) |
| Molar Refractivity                       | 117.31 ± 0.3 cm<sup>3</sup> |
| Molar Volume                             | 376.1 ± 3.0 cm<sup>3</sup>  |
| Parachor                                 | 928.8 ± 6.0 cm<sup>3</sup>  |
| Index of Refraction                      | 1.536 ± 0.02               |
| Surface Tension                          | 37.1 ± 3.0 dyne/cm         |
| Density                                  | 1.048 ± 0.06 g/cm<sup>3</sup> |
| Polarizability                           | 46.50 ± 0.5 × 10<sup>-24</sup> cm<sup>3</sup> |
| Monoisotopic Mass                        | 394.28718 Da               |
| Nominal Mass                             | 394 Da                     |
| Average Mass                             | 394.5894 Da                |

**Figure 5.** Active site-loop of the target protein (GLY 240, GLY241, GLY242).

| Table 2. The calculated docking results of the minimum energy value for the protein-ligand complex |
|--------------------------------------------------------------------------------------------------|
| Docking correlations for 2B0P:MOL2 done in 13 min, 3 sec.                                     |
| Main pass done in 1 min, 27 sec: 146517 orientations/sec. Evaluated 976004352 orientations    |
| Starting orientation [$\alpha=0$] (Energy=245.92) ranked 424460 in the search                   |
| Energy range: $E_{\text{min}} = -209.54$, $E_{\text{max}} = -101.11$                        |
| Clustering found 68 clusters from 500 docking solutions in 0.03 seconds                        |
| $E_{\text{total}} = -209.5$, $E_{\text{shape}} = -209.5$, RMS -1.00                         |
tivity. The mechanisms of action of tea tree oil and three of its components, 1,8-cineole, terpinen-4-ol, and -terpineol, against *S. aureus* ATCC 9144 were investigated (9). Some antimicrobial agents cause gross membrane damage and provoke whole-cell lysis (12, 30). The failure of TTO or its components to lyse *S. aureus* cells suggests that their primary mechanism of action is not gross cell wall damage. Treatment-induced release of membrane-bound cell wall autolytic enzymes will induce lysis eventually (16), the activation of autolytic enzymes may have been responsible for this effect, the lysis may also have been due to weakening of the cell wall and the subsequent rupture of the cytoplasmic membrane due to osmotic pressure (rather than a specific action on the cytoplasmic membrane) (9).

**Figure 6.** Substrate binding cleft and Protein ligand complex.

**Figure 7.** Hydrogen bonds (H-bond) interaction.

**Figure 8.** Hydrogen bonds (H-bond) interaction.
From the above cited literature, it is evident that the terpenoid under study can inhibit all the above mentioned hypotheses.

Hence we conclude from our docking study that, the novel terpenoid isolated from *E. scaber* possesses antibacterial activity (*S. aureus*) by inhibiting the autolysin.

ACKNOWLEDGEMENT

This project is funded by BTIS (Biotechnology Information System), DBT (Department of Biotechnology), Ministry of Science and Technology, Government of India, India.

REFERENCES

1. Avani, KS Neeta. A study of the antimicrobial activity of *Elephantopus scaber*. *Indian J. Pharm.* 2005; 37: 126-127.
2. Ayafor JF, Tchuendem MHK, Nyasse V. Novel bioactive diterpenoids *Aframomum Aulacocarpos*. *J. Nat. Prod.* 1994; 57: 917-923.
3. Ayyagari A, Bhargava A. β-Lactamases and their clinical significances. A mini review. *Hosp. Today.* 2001; 6: 1-6.
4. Bauer AW, Kirby WMN, Sherris JC, Tuck M. Antibiotics susceptibility testing by a standardized single disc method. *IS J. Clin. Pathol.* 1996; 24: 617-628.
5. Bacteriol. Rev. 1963; 27: 18.
6. Bisignano SA, Smith TJ, Foster SJ. The role of autolysins during vegetative growth of *Bacillus subtilis* 168. *Microbiology* 1998; 144: 73-82.
7. Brucocleri RE, Olafson BD, States DJ, et al. A Program for Macromolecular Energy, Minimization, and Dynamics Calculations, edited by Brooks BR. *J. Comp. Chem.* 1983; 4: 187-217.
8. PVR Schleyer, et al. CHARMM: The Energy Function and Its Parameterization with an Overview of the Program, in The Encyclopedia of Computational Chemistry, by MacKerell AD Jr., Brooks B, Brooks CL III, Nilsson L, Roux B, Won Y, Karplus M. 1998; 1: 271-277.
9. Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. *J. Appl. Bacteriol.* 1995; 78: 264-269.
10. Carton JA, Maradona JA, Nuno FJ, et al. Diabetes mellitus and bacteremia: A comparative study between diabetic and non diabetic patients. *Eur. J. Med.* 1992; 1: 281-287. [PubMed]
11. Cas PA, Vlietinck J, Berge DV, et al. Anti-infective potential of natural products: How to develop a stronger *in vitro* proof-of-concept. *J. Ethanopharmacol.* 2006; 19: 290-302.
12. Denyer SP, Hugo WB. Biocide-induced damage to the bacterial cytoplasmic membrane, In S. P.Mechanisms of action of chemical biocides: their study and exploitation. *Oxford, United Kingdom: Blackwell Scientific Publications.* 1991; 171-187.
13. Firczek M, Mucha A, Bochtler M. Crystal structures of active LytM. *J. Mol. Biol.* 2005; 354: 578-590.
14. Foster SJ. The role and regulation of cell wall structural dynamics during differentiation of endospore-forming bacteria. *J. Appl. Bacteriol.* 1994; 76: S25-S39.
15. Forsberg C, Rogers HT. Autolytic Enzymes in Growth of Bacteria. *Nature.* 1971; 229: 272-273 (22 January 1971); doi: 10.1038/229272a0.
16. Gilbert P. The revival of microorganisms sublethally injured by chemical inhibitors. In Andrews MHE, Russell AD (ed.), the revial of injured microbes. *London, United Kingdom: Academic Press.* 1984; 175-197.
17. Hammer KA, Carson CF, Riley TV. Antimicrobial activity of essential oil and other plant extracts. *J. Applied Microbiol.* 1999; 86: 985-990.
18. Harborne JB. Methods of Plant Analysis. In: Phytochemical Methods. *London: Chapman and Hall.* 1973; 132.
19. Higgins ML, Pooley HM, Shockman GD. Site of Initiation of Cellular Autolysis in *Streptococcus faecalis* as Seen by Electron Microscopy. *J. Bacteriol.* 1970 Aug; 103 (2): 504-512. [PubMed]
20. Jasmine R, Daisy P, Selvakumar BN. A Novel Terpenoid from *Elephantopus scaber* with Antibacterial Activity Against Beta lactamase-Producing Clinical Isolates . *Research Journal of Microbiology.* 2007; 2 (10): 770-775.
21. Kiffer CR, Mendes C, Oplustil CP, et al. Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. *INT. Braz. J. Urol.* 2007; 33: 42-49.
22. Lis-Balchin M, Deans SG. Antimicrobial effects of hydrophilic dyes: Antimicrobial activities. *Phytother. Res.* 1996; 9: 346-350.
23. Lominskim I, Cameron J, Wylle G. Chaining and unchaining *Strep- tococcus faecalis*; a hypothesis of the mechanism of bacterial cell separation.*Nature.* 1958 May 24; 181 (4621): 1477.
24. MacFarlane IA, Brown RM, Smyth RW, et al. *Ethanopharmacol.* 1998; 1: 205-207.
25. Lominskim I, Cameron J, Wylle G. Chaining and unchaining Streptococcus faecalis; a hypothesis of the mechanism of bacterial cell separation.*Nature.* 1958 May 24; 181 (4621): 1477.
26. Miles RS, Amyes SGB. Laboratory Control of Antimicrobial Therapy. In: Practical Medical Microbiology. Collee JG, Fraser AG, Marmion BP, Simmons A (Eds.), 14th Edition. *Newyork: Churchill Livingstone.* 1996; 167.
27. Perkins HR. Chemical structure and biosynthesis of bacterial cell walls. *Bacteriol. Rev.* 1963; 27: 18.
28. Picazo JJ, Betriu C, Rodriguez-Avil I, et al. Antimicrobial resistance surveillance: VIRA STUDY. *Enfmir. Infecc. Microbiol. Clin.* 2006; 24: 617-628.
28. Pozzilli P, Lesli RDG. Infections and diabetes: Mechanisms and prospects for prevention. *Diabet Med.* 1994; 11: 935-941. [PubMed].
29. Rogers HJ. The bacterial cell wall. The result of adsorption, structure, or selective permeability. *J. Gen. Microbiol.* 1968; 32: 19.
30. Russell AD, Morris A, Allwood MC. Methods for assessing damage to bacteria induced by chemical and physical agents. *Methods Microbiol.* 1973; 8: 95-182.
31. Shockman GD. Unbalanced cell-wall synthesis: autolysis and cell-wall thickening. *Bacteriol Rev.* 1969; 29: 345.
32. Shockman GD, Höltje JV. Microbial peptidoglycan (murein) hydrolases. In: *Bacterial Cell Wall.* Edited by Ghuysen JM, Hakenbeck R. *Amsterdam: Elsevier.* 1994; 131-166.
33. Supriya S Tankhewale, Suresh V, *et al.* Evaluation of extended spectrum β-Lactamase in urinary isolates. *Indian J. Med. Res.* 2004; 120: 553-556.